Nasdaq Sets Nov. 9 Delisting Date; Shares Halted Pending Appeal
MCTA has more than doubled off its 52-week low of $4.3 on elevated volume (4.9× avg).
Summary
Nasdaq notified Charming Medical that its securities will be delisted on Nov. 9, 2026 unless the company appeals to a Hearings Panel. Trading is already halted and stays frozen until any appeal is resolved, so holders have no exit right now. The delisting falls under Nasdaq Rule IM-5101-4, the public-interest provision, which points to elevated concerns beyond a simple bid-price shortfall. This follows the 6-K filed Sept. 29 for an Oct. 23 EGM to cancel Class B shares and remove directors, and it traces back to a prior SEC trading suspension on Nov. 26, 2025. If the appeal fails, the shares may move to OTC trading, where spreads are typically wider and liquidity thinner.
At the time of this announcement, MCTA was trading at $29.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $438.5M. The 52-week trading range was $4.30 to $31.70. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.